Breast cancer is the most common cancer in women in the Western world. Because breast cancer is estrogendependent, reducing estrogen secretion by oophorectomy
For some women with breast cancer, taking adjuvant tamoxifen (Nolvadex) for 10 years after primary treatment leads to a greater reduction in breast cancer recurrences and deaths than taking the drug for only 5 years, according to the results of a large international clinical trial.
Tamoxifen is approved by the FDA for adjuvant hormone treatment of premenopausal and postmenopausal women (and men) with ERpositive earlystage breast cancer, and the aromatase inhibitors anastrozole and letrozole are approved for this use in postmenopausal women.
In women who had ERpositive disease (n 10, 645), tamoxifen significantly reduced the longterm risk for breast cancer recurrence and death. The relative risk (RR) for
Find information about tamoxifen, a medicine to treat breast cancer, from Cleveland Clinic, including side effects, precautions, concerns, and more.
Side effects for men with breast cancer taking Tamoxifen include headaches, nausea, hot flashes, skin rash, fatigue, sexual dysfunction, and weight and mood changes.
Tamoxifen blocks the effects of estrogen on breast cancer cells, thereby stopping the growth of these cells in the body. This drug is effective only for breast cancers that are estrogenreceptor positive.
For women with hormone receptorpositive breast cancer treated with surgery, tamoxifen can help lower the chances of the cancer coming back and raise the chances of living longer. It can also lower the risk of getting a new cancer in the other breast.
Tamoxifen can be an effective drug for treatment and risk reduction of breast cancer. Learn more today.
In a study of more than 13, 000 women at high risk for breast cancer, scientists found that women who took tamoxifen for 5 years had fewer breast cancers than women who